Faiza Naseer, Kousain Kousar, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad
{"title":"Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation","authors":"Faiza Naseer, Kousain Kousar, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00278-y","DOIUrl":"https://doi.org/10.1186/s12645-024-00278-y","url":null,"abstract":"<br/><p><b>Retraction Note: Cancer Nanotechnology (2023) 14:65</b> <b>https://doi.org/10.1186/s12645-023-00218-2</b></p><br/><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding some of the images presented in the figures, specifically:</p><ul>\u0000<li>\u0000<p>Fig. 6 appears highly similar to Fig. 10 of Naseer et al. (2023)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 6 Pure VC 12 h 90 ug/ml and VC-loaded TCs-HA 24 h 50 ug/ml images appear highly similar</p>\u0000</li>\u0000<li>\u0000<p>Fig. 17 A5 and Fig. 18 D5 images appear to overlap (flipped and with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 18 C6 and D6 appear to overlap (with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Several panels in Figs. 17 and 18 appear highly similar to those in Fig. 8 of Kousar et al. (2023)</p>\u0000</li>\u0000</ul><p>The authors have been unable to provide the underlying raw data upon request. The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated thiolated chitosan as a green nanoformulation for the treatment of prostate cancer: a viro-immunotherapeutic approach. Int J Nanomed 18:185–205. https://doi.org/10.2147/IJN.S386560</p><p>Article CAS Google Scholar </p></li><li><p>Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Faiza Naseer, Kousain Kousar & Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Department of Biology, University of Hail, Hail, Saudi Arabia</p><p>Sadia Anjum</p></li></ol><span>Authors</span><ol><li><span>Faiza Naseer</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Sch","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141772924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Malgorzata Sikorska, Grzegorz Domanski, Magdalena Bamburowicz-Klimkowska, Artur Kasprzak, Anna M. Nowicka, Monika Ruzycka-Ayoush, Ireneusz P. Grudzinski
{"title":"Studies on the thermal sensitivity of lung cancer cells exposed to an alternating magnetic field and magnesium-doped maghemite nanoparticles","authors":"Malgorzata Sikorska, Grzegorz Domanski, Magdalena Bamburowicz-Klimkowska, Artur Kasprzak, Anna M. Nowicka, Monika Ruzycka-Ayoush, Ireneusz P. Grudzinski","doi":"10.1186/s12645-024-00276-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00276-0","url":null,"abstract":"Magnetic fluid hyperthermia (MFH) represents a promising therapeutic strategy in cancer utilizing the heating capabilities of magnetic nanoparticles when exposed to an alternating magnetic field (AMF). Because the efficacy and safety of MFH treatments depends on numerous intrinsic and extrinsic factors, therefore, the proper MFH setups should focus on thermal energy dosed into the cancer cells. In this study, we performed MFH experiments using human lung cancer A549 cells (in vitro) and NUDE Balb/c mice bearing human lung (A549) cancer (in vivo). In these two experimental models, the heat was induced by magnesium-doped iron(III) oxide nanoparticles coated with mPEG-silane (Mg0.1-γ-Fe2O3(mPEG-silane)0.5) when exposed to an AMF. We observed that the lung cancer cells treated with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 (0.25 mg·mL−1) and magnetized for 30 min at 14.4 kA·m−1 yielded a satisfactory outcome in reducing the cell viability up to ca. 21% (in vitro). The activation energy calculated for this field strength was estimated for 349 kJ·mol−1. Both volumetric measurements and tumor mass assessments confirmed by magnetic resonance imaging (MRI) showed a superior thermal effect in mice bearing human lung cancer injected intratumorally with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 nanoparticles (3 mg·mL−1) and subjected to an AMF (18.3 kA·m−1) for 30 min four times at weekly intervals. Research demonstrated that mice undergoing MFH exhibited a marked suppression of tumor growth (V = 169 ± 94 mm3; p < 0.05) in comparison to the control group of untreated mice. The CEM43 (cumulative number of equivalent minutes at 43 °C) value for these treatments were estimated for ca. 9.6 min with the specific absorption rate (SAR) level ranging from 100 to 150 W·g−1. The as-obtained results, both cytotoxic and those related to energy calculations and SAR, may contribute to the advancement of thermal therapies, concurrently indicating that the proposed magnetic fluid hyperthermia holds a great potential for further testing in the context of medical applications. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer","authors":"Leila Farhoudi, Seyedeh Maryam Hosseinikhah, Amin Kazemi-Beydokhti, Leila Arabi, Seyedeh Hoda Alavizadeh, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari","doi":"10.1186/s12645-024-00275-1","DOIUrl":"https://doi.org/10.1186/s12645-024-00275-1","url":null,"abstract":"Designing and preparing a co-delivery system based on polymeric micelles have attracted in recent years. Co-delivery of anti-cancer agents within pH-sensitive polymeric micelles could provide superior advantages over the co-administration of free drugs, since it enables simultaneous delivery of drugs to reach an optimum synergistic dose right to the tumor. DOX was conjugated to the polymer through a hydrazine linker by Schiff’s base reaction. Then, DTX was encapsulated into the core of the polymer to the resulting DOX-Hyd-PM/DTX micelle with optimum molar ratios of 1:1 and 1:5 (DOX/DTX). The final formulations showed the desired particle size and increased release of DOX and DTX in acidic media (pH 5.5). The cytotoxicity assay of DOX-Hyd-PM/DTX indicated the highest synergistic effect on both 4T1 and TUBO cell lines over other formulations. Interestingly, in accordance with in vitro results, DOX-Hyd-PM/DTX revealed a promising anti-tumor activity in mice-bearing 4T1 breast cancer tumor with higher tumor accumulation of DOX and DTX after 24 h compared to free drugs combination. These findings point to the potential use of such smart nanodrug delivery systems in cancer treatment, where the synergistic effect of both drugs may be used to enhance therapeutic response. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Resveratrol-based nano-formulations as an emerging therapeutic strategy for ovarian carcinoma: autophagy stimulation and SIRT-1/Beclin/MMP-9/P53/AKT signaling","authors":"Mai O. Kadry","doi":"10.1186/s12645-024-00274-2","DOIUrl":"https://doi.org/10.1186/s12645-024-00274-2","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141644885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma","authors":"Aimi Huang, Fuchuang Zhang, Jiyang Zhang, Xiaoya Xu, Zhikuan Li, Sheng Chen, Baoning Nian, Dadong Zhang, Baohui Han, Aiqin Gu, Weimin Wang","doi":"10.1186/s12645-024-00273-3","DOIUrl":"https://doi.org/10.1186/s12645-024-00273-3","url":null,"abstract":"Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Here, we investigated the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for anlotinib efficacy. A total of 20 advanced NSCLC patients were enrolled. Patients were classified as having stable disease (SD) or progressive disease (PD) after the initial efficacy assessment. Seven differentially expressed miRNAs (DEMs) were identified. Among them, miR-941 was significantly upregulated in the PD group, while the others were downregulated. Furthermore, these six downregulated miRNAs (miR-30a-3p, miR-150-5p, miR-122-5p, miR-10b-5p, miR-92a-3p, and miR-150-3p) were more pronounced in nonsmoking patients. It was found that sEV miRNAs have the potential to predict the benefit of anlotinib.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Biocompatible PLGA-PCL nanobeads for efficient delivery of curcumin to lung cancer","authors":"Sheida Sadeghi, Javad Mohammadnejad, Akram Eidi, Hanieh Jafary","doi":"10.1186/s12645-024-00272-4","DOIUrl":"https://doi.org/10.1186/s12645-024-00272-4","url":null,"abstract":"Lung cancer has been mentioned as the first and second most prevalent cancer among males and females worldwide, respectively since conventional approaches do not have enough efficiency in its suppression. Therefore, a biocompatible and efficient polylactic-co-glycolic acid (PLGA: P)- poly-ε-caprolactone (PCL: P) copolymer was fabricated for delivery of relatively insoluble curcumin (Cur) to A549 lung cancer cells. Next, the physicochemical aspects of the synthesized nanobeads were characterized by applying analytical sets, including FT-IR, DLS, TEM, and TGA as nano-metric size (20–45 nm) and 1.29% of Cur entrapment efficiency were determined for P-P-Cur nano-beads. Thereafter, a controlled (5% within 2 h at pH 7.4) and pH-sensitive (nearly 50% within 4 h at pH 5.0) drug release manner was observed for P-P-Cur nanobeads. Thereafter, biomedical assays were conducted for the cancer suppression ability of nanobeads. 41% cell viability after 24 h of treatment with 200 nM concentration and 7.55% cell cycle arrest at 5 h of post-treatment with 100 nM (IC50) concentration were attained for P-P-Cur. Also, 7-fold increase and 2-fold decrease in the expressions of Caspase-9 (apoptotic gene) and Bcl2 (anti-apoptotic gene) were observed which have further approved the cancer inhibition potency of the P-P-Cur sample. The cellular uptake results indicated 91% internalization in A549 cells while it was less than 1% for the pure Cur. These data have demonstrated that P-P-Cur can use as a biocompatible drug delivery system for Cur and treatment of lung cancer.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141530125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neda Mahdizadeh, Mahtab Khorshid Shabestari, F. Tafvizi, Parvin Khodarahmi
{"title":"Delivery of letrozole-encapsulated niosomes via a 3D bioprinting gelatin–alginate scaffold for potential breast cancer treatment","authors":"Neda Mahdizadeh, Mahtab Khorshid Shabestari, F. Tafvizi, Parvin Khodarahmi","doi":"10.1186/s12645-024-00271-5","DOIUrl":"https://doi.org/10.1186/s12645-024-00271-5","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141336285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anand Kumar Veeramachineni, T. Sathasivam, R. Paramasivam, Saravanan Muniyandy, Shafii Bin Khamis, Yau Yan Lim, J. Pushpamalar
{"title":"Correction: Carboxymethyl-sagocellulose-stabilized Fe3O4 nanoparticles with 5-fuorouracil as photothermal agents for tumor ablation","authors":"Anand Kumar Veeramachineni, T. Sathasivam, R. Paramasivam, Saravanan Muniyandy, Shafii Bin Khamis, Yau Yan Lim, J. Pushpamalar","doi":"10.1186/s12645-024-00263-5","DOIUrl":"https://doi.org/10.1186/s12645-024-00263-5","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141344393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shengjie Ye, Xier Pan, Lei Zhang, Yanlong Hong, Kaili Hu
{"title":"Correction: HepG2 exosomes coated luteolin nanoparticles remodeling hepatic stellate cells and combination with sorafenib for the treatment of hepatocellular carcinoma","authors":"Shengjie Ye, Xier Pan, Lei Zhang, Yanlong Hong, Kaili Hu","doi":"10.1186/s12645-024-00268-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00268-0","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141338874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}